Skip to content
value.today

Inozyme Pharma, Inc.

🇺🇸 Boston, Massachusetts, USAPharmaceuticalsFounded 2015
Total raised
$116 M
2 rounds on record
Latest round
$67 M
Nov 2018
First round on record
Jan 2017
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Inozyme Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$67 MNo. 2$50 to $250 million

Inozyme Pharma, Inc.: Raise no. 2, Nov 2018

Investors in this round

12 investors had bought by the notice of Jun 8, 2020: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Inozyme Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$67 M of $67 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Axel Bolte · Executive Officer, Director
  • Douglas Treco · Director
  • Edward Mathers · Director
  • Lynne Sullivan · Director
  • Martin Edwards · Director
  • Reinaldo Diaz · Director
  • Rob Hopfner · Director
  • Sarah Bhagat · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Axel Bolte, Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Jun 8, 2020. Read the notice at the SEC.

equitySEC
Jan 2017$49 MNo. 1$10 to $50 million

Inozyme Pharma, Inc.: Raise no. 1, Jan 2017

Investors in this round

14 investors had bought by the notice of Nov 21, 2018: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Inozyme Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$49 M of $49 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Axel Bolte · Executive Officer, Director
  • Joseph Schlessinger · Executive Officer, Director
  • Edward Mathers · Director
  • Martin Edwards · Director
  • Reinaldo Diaz · Director
  • Rob Hopfner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Axel Bolte, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 21, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Inozyme Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2020

That is all the official record says: Inozyme Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

17 named in official filings. Open an investor to see everything it has backed.

Investors in Inozyme Pharma, Inc.
InvestorKindAmountRoundRoleSource
Alexion Pharmaceuticals, Inc.Companynot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Joseph SchlessingerPersonnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Longitude Capital Partners III, LLCFund or asset managernot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Longitude Venture Partners III, L.P.Venture capitalnot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Nea 15 GP, LLCOthernot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
NEA Partners 15, L.P.Fund or asset managernot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
New Enterprise Associates 15, L.P.Fund or asset managernot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Pivotal bioVenture Partners Fund I G.P., L.P.Venture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Pivotal bioVenture Partners Fund I, L.P.Venture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Pivotal bioVenture Partners Fund I U.G.P., LtdVenture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Rock Springs Capital LLCFund or asset managernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Rock Springs Capital Management LPFund or asset managernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Rock Springs Capital Master Fund LPFund or asset managernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Sofinnova Management X, L.L.C.Fund or asset managernot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Sofinnova Venture Partners X, L.P.Venture capitalnot statednot statedHeld Series A-2 preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Inozyme Pharma, Inc.
NameRoleNamed in
Axel BolteExecutive officerJun 2020
Joseph SchlessingerExecutive officerNov 2018
Axel BolteDirectorJun 2020
Douglas TrecoDirectorJun 2020
Edward MathersDirectorJun 2020
Lynne SullivanDirectorJun 2020
Martin EdwardsDirectorJun 2020
Reinaldo DiazDirectorJun 2020
Rob HopfnerDirectorJun 2020
Sarah BhagatDirectorJun 2020
Joseph SchlessingerDirectorMar 2020